FI924529A0 - Nya 17b-substituerade aza-androstan-derivat - Google Patents

Nya 17b-substituerade aza-androstan-derivat

Info

Publication number
FI924529A0
FI924529A0 FI924529A FI924529A FI924529A0 FI 924529 A0 FI924529 A0 FI 924529A0 FI 924529 A FI924529 A FI 924529A FI 924529 A FI924529 A FI 924529A FI 924529 A0 FI924529 A0 FI 924529A0
Authority
FI
Finland
Prior art keywords
phe
formula
group
nya
aza
Prior art date
Application number
FI924529A
Other languages
English (en)
Other versions
FI924529A (fi
Inventor
Michel Biollaz
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI924529A0 publication Critical patent/FI924529A0/fi
Publication of FI924529A publication Critical patent/FI924529A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI924529A 1991-10-09 1992-10-07 Nya 17b-substituerade aza-androstan-derivat FI924529A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH297891 1991-10-09

Publications (2)

Publication Number Publication Date
FI924529A0 true FI924529A0 (fi) 1992-10-07
FI924529A FI924529A (fi) 1993-04-10

Family

ID=4245915

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924529A FI924529A (fi) 1991-10-09 1992-10-07 Nya 17b-substituerade aza-androstan-derivat

Country Status (19)

Country Link
US (2) US5304562A (fi)
EP (1) EP0538192B1 (fi)
JP (1) JPH05213989A (fi)
KR (1) KR930007969A (fi)
AT (1) ATE152121T1 (fi)
AU (1) AU657579B2 (fi)
CA (1) CA2080054A1 (fi)
DE (1) DE59208383D1 (fi)
DK (1) DK0538192T3 (fi)
ES (1) ES2101073T3 (fi)
FI (1) FI924529A (fi)
GR (1) GR3024013T3 (fi)
HU (1) HUT62600A (fi)
IL (1) IL103361A (fi)
MX (1) MX9205792A (fi)
NO (1) NO923911L (fi)
NZ (1) NZ244640A (fi)
TW (1) TW263513B (fi)
ZA (1) ZA927747B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
AU5323694A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
CA2231041A1 (en) * 1995-09-15 1997-03-20 Raman K. Bakshi 4-azasteroids for treatment of hyperandrogenic conditions
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
EP0271219B1 (en) * 1986-11-20 1992-07-29 Merck & Co. Inc. Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
ATE170753T1 (de) * 1989-07-07 1998-09-15 Endorecherche Inc Androgenderivate zur hemming der aktivität der sexualsteroide
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives

Also Published As

Publication number Publication date
HUT62600A (en) 1993-05-28
GR3024013T3 (en) 1997-10-31
ZA927747B (en) 1993-04-13
IL103361A0 (en) 1993-03-15
NO923911D0 (no) 1992-10-08
EP0538192A1 (de) 1993-04-21
AU657579B2 (en) 1995-03-16
NZ244640A (en) 1994-12-22
IL103361A (en) 1997-06-10
FI924529A (fi) 1993-04-10
CA2080054A1 (en) 1993-04-10
DK0538192T3 (da) 1997-05-20
DE59208383D1 (de) 1997-05-28
US5378710A (en) 1995-01-03
KR930007969A (ko) 1993-05-20
EP0538192B1 (de) 1997-04-23
HU9203189D0 (en) 1992-12-28
JPH05213989A (ja) 1993-08-24
US5304562A (en) 1994-04-19
MX9205792A (es) 1993-08-01
ES2101073T3 (es) 1997-07-01
TW263513B (fi) 1995-11-21
AU2626192A (en) 1993-04-22
ATE152121T1 (de) 1997-05-15
NO923911L (no) 1993-04-13

Similar Documents

Publication Publication Date Title
FI924529A (fi) Nya 17b-substituerade aza-androstan-derivat
HUP0002495A1 (hu) VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69103206T2 (de) Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel.
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
ES2057126T3 (es) Metodo de tratamiento de la caquexia y algunos nuevos compuestos para utilizar en este metodo.
PH25859A (en) Composition for treatment of ischemic disorder
NO163735C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkyl-beta-carboliner.
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
AU3381389A (en) Derivative of caffeic acid and pharmaceutical composition containing the same
NO167746C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive muramylpeptidderivater.
FI911016A0 (fi) Menetelmä farmakologisesti aktiivisten substituoitujen -diketonien valmistamiseksi
AU576887B2 (en) 1,6-naphthyridine derivatives
NO173057C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzanilidderivater
AU2747492A (en) Butyric acid derivatives
ATE61355T1 (de) 2,5-dimethylpyrrolderivative, ihre herstellung und ihre verwendung.
DE3880092T2 (de) Antibiotika der Mureidomycin-Gruppe, deren Herstellung und deren Verwendung.
FI871253A (fi) 1-/3-(2-dialkylaminoetoxi)-2 -tienyl/-3-fenyl-1-propanoner och deras syraadditionssalter, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska sammansaettningar.
DE69105618D1 (de) Derivate des 1,2,5,6-Tetrahydropyridin-3-caboxaldehydoxims, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FD Application lapsed